Drug intelligence / Profile preview

freund's adjuvant

Development stage
Unknown
Lead developer
Jules T. Freund
Administration
Subcutaneous, Intraperitoneal
01

Overview

Freund's adjuvant is an immunopotentiating agent comprised of mineral oil, emulsifier (mannide monooleate), and, in its complete form, heat-killed mycobacteria (usually Mycobacterium tuberculosis)[1][4][8]. There are two principal forms: Complete Freund’s Adjuvant (CFA), which includes mycobacteria, and Incomplete Freund’s Adjuvant (IFA), which lacks the mycobacterial component[1]. As a water-in-oil emulsion, the adjuvant retains antigen at the injection site and dramatically amplifies the immune response by inducing robust local inflammation, promoting recruitment and activation of antigen-presenting cells (e.g., macrophages), and resulting in potent activation of T helper cells and antibody production[1][3][4][5][9]. Due to severe inflammatory toxicity, its use is restricted to research in laboratory animals; it is not approved for use in humans[1][5][7][9].

Brand names
Freund's Complete AdjuvantCFAVax
Other names
freund's adjuvantfreund's complete adjuvantfreund's incomplete adjuvantFCACFAfreund's adjuvant completefreunds complete adjuvantadjuvant complete freundfreund's complete adfreund's complete adjuvant modified
02

Targets

PRR (Pattern recognition receptors)

Beyond the preview

Go deeper on freund's adjuvant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on freund's adjuvant.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call